Researchers at the Francis Crick Institute and University College London (UCL) have identified a 14-protein signature in the blood that could identify who would benefit from cancer prevention drugs. 

The signature enabled the team, funded by Cancer Research UK and the European Research Council (ERC), to predict lung cancer risk more than five years before diagnosis. 

Currently, lung cancer screening is offered only to people over a certain age who have previously smoked, missing never-smokers and individuals exposed to high levels of pollutants who may also be at risk of the disease. 

Published in Cell, the team applied machine learning to blood plasma protein data from more than 48,000 UK Biobank participants, using matched cancer registry records to identify those who later developed lung cancer. 

Along with age, smoking status and previous history of lung disease, the machine learning algorithm identified 14 key proteins in the blood that could predict a future diagnosis of lung cancer within five years. The team validated this protein signature in eight datasets from across the world, finding that it was higher in patients who, in the future, developed lung cancer in all studies, including one cohort of non-smokers.  

Analysis of the signature in patients and animal models suggested that the signature does not come from the tumour itself, but reflects an altered inflammatory lung environment that precedes cancer. The signature was also increased in people who later developed idiopathic pulmonary fibrosis or chronic obstructive pulmonary disease (COPD). 

Blocking IL-1β slowed tumour development 

The lab’s earlier work showed that air pollution exposure triggers immune cells in the lung to release an inflammatory signal called interleukin-1 beta (IL-1β), which can wake up dormant cells carrying cancer-causing mutations. 

In this study, they show that pollution exposure simultaneously increases the signature proteins and boosts the population of ‘KAC cells’, an adaptive cell state that occurs in response to injury but can also become cancerous if mutations are present. The researchers showed that mutant cells from several different lung cell types all enter the same KAC state on their way to cancer, and that air pollution expanded this pool of KAC cells and increased the 14-protein signature. 

The team also found that components of the signature were increased in the presence of IL-1β linked to air pollution. Blocking IL-1β in mice exposed to pollution reduced the number of KAC cells and slowed early tumour development, suggesting anti-IL-1β drugs could prevent lung cancer in people whose lungs are showing this inflammatory signal. 

Comparable to cardiovascular prevention strategies 

In 2017, Novartis’s CANTOS trial tested the IL-1β blocker canakinumab to prevent cardiovascular disease, and reported that the drug also reduced lung cancer incidence. However, the benefit was modest at a population level. 

Re-analysing data from 4,651 CANTOS participants, the researchers found that people with a high baseline 14-protein signature were the ones who clearly benefited from canakinumab, with their lung cancer risk almost halved. By selecting only those with a high signature, the number of people needed to treat to prevent one incidence of lung cancer was 55, comparable to established cardiovascular prevention strategies such as statins. 

Charlie Swanton, Clinical Research Director and Principal Group Leader at the Crick, Professor in Cancer at UCL and lead investigator for TRACERx, said: “Drugs like statins have transformed the prevention of cardiovascular disease, used to treat individuals with a high ‘low density lipoprotein’ (LDL). Finding a signal for an inflammatory state in the lungs has given us insight into this window of opportunity, when preventative treatment could work best.”